SoC and SoC alone gained 0.3155 QALYs and 0.2752 QALYs, respectively. Hence, ranolazine plus SoC resulted in an ICER of € 4,620 per QALY gained, well below the threshold of € 34,000 per QALY gained, that is twice the annual per capita income. The PSA showed that the likelihood of ranolazine plus SoC being cost-effective at the threshold of € 34,000 per QALY gained was 100%. ConClusions: The results suggest that ranolazine as add-on treatment may be a cost-effective alternative for the symptomatic treatment of patients with chronic stable angina in Greece.
objeCtives: To evaluate the cost-effectiveness of apixaban vs. existing therapeutic alternatives (fondaparinux/VKA, LMWH/VKA, rivaroxaban, dabigatran) in the acute treatment and prevention of venous thromboembolism (VTE) from the French National healthcare insurance perspective. Methods: A cohort of simulated patients with VTE were placed on one of five therapeutic strategies for 6-months and tracked over a course of 5-years in a Markov model. Modeled clinical events included recurrent VTE, major bleed, clinically-relevant non-major bleed, chronic thromboembolic pulmonary hypertension, post-thrombotic syndrome and death. Data on efficacy and safety were derived from a network meta-analysis. Medical costs of clinical events were extracted from a dedicated analysis of French health administrative databases and utility data were derived from literature. To assess the costs and benefits of extended treatment, treatment durations of 12 and 18 months were examined in scenario analyses. Additionally, probabilistic sensitivity analyses that accounted for uncertainty in model parameters were conducted for each comparator. Results: Over treatment duration of 6 months at lifetime time horizon, apixaban was the dominant (less costly and more effective) alternative (6,573€ and 3.38 QALYs) compared to fondaparinux/VKA (6,621€ and 3.37 QALYs), LMWH/VKA (6,639€ and 3.37 QALYs), rivaroxaban (6,734€ and 3.38 QALYs) and dabigatran (6,732€ and 3.37 QALYs). Probabilistic sensitivity analyses revealed apixaban was more likely to be cost-effective than all other strategies. Considering an extended treatment duration of 12 months, apixaban remained dominant versus rivaroxaban and dabigatran but cost-effective compared to fondaparinux/VKA (ICUR: 3,098€ /QALY) and LMWH/VKA (ICUR 2,381€ /QALY). Similar results were observed for treatment duration of 18 months with an increase of ICUR to 5,634€ /QALY and 5,083€ /QALY, respectively. ConClusions: Apixaban can offer substantial clinical and economic benefits over alternative therapies for acute and extended treatment of VTE. objeCtives: To conduct a systematic review on the pharmacoeconomic value of ranolazine vs standard-of-care (SOC) for the treatment of symptomatic chronic stable angina (CSA). Methods: Medline, Cochrane Library and Cost-Effectiveness Analysis Registry without time limits were searched. Articles in English were identified with the following keywords: cost, economic, ranolazine, ranexa, angina, coronary artery disease. The identified studies were independently reviewed by two investigators against pre-determined inclusion and exclusion criteria. The Quality of Health Economic Studies scale was used to assess the quality of the included studies. The data of selected studies were extracted onto a data extraction form and consequently were synthesized. Costing and effectiveness data for each comparator, incremental cost per quality-adjusted-life year (QALY) gained and results from sensitivity analyses were extracted. Results: Five studies containing evidence on effectiveness and cost of ranolazine were included in the review. Four of these studies assessed the cost-utility of ranolazine added to SOC compared to SOC alone, using decision tree or Markov models whereas one was a retrospective cost-comparative study. In all studies, patients were stratified according to their angina frequency symptoms. The analysis was conducted from a payer perspective in 4 studies and from the societal perspective in 1 study. The time horizon of analysis did not exceed the 1 year at any study. Ranolazine appeared to be cost-effective since it reduced the number of angina-related hospitalizations and improved quality of life with an Incremental Cost-Effectiveness Ratio (ICER) varying from € 4,000 to € 15,000 per QALY gained. The ranolazine acquisition cost was the variable that mainly drove the ICER. ConClusions: The existing evidence showed that ranolazine is cost-effective for the second-line treatment of patients with symptomatic CSA, added to SOC. Further research is required to evaluate the cost -effectiveness of ranolazine in each angina frequency group. objeCtives: This evaluation aimed to assess the cost-effectiveness of edoxaban 60mg versus warfarin for the prevention of stroke and systemic embolic events among patients with non-valvular atrial fibrillation (NVAF) in the UK, from the perspective of the NHS. Methods: A Markov model was developed to simulate the course of disease in hypothetical cohorts of patients with NVAF and to assess the cost-effectiveness of edoxaban versus the current UK standard of care, warfarin. The model used data from the ENGAGE study, and was based on patients with CHADS2 ≥ 2. Utility values were derived from systematic literature reviews. Costs were extracted from the literature and the NHS reference cost database; both were discounted at 3.5% per annum. Health outcomes were assessed in quality-adjusted life years (QALYs), and evaluated over a lifetime time horizon. Deterministic and probabilistic sensitivity analyses (PSA) were conducted to evaluate the effect of uncertainty in input parameters on the results. Results: In the base case analysis (CHADS2 ≥ 2), the incremental cost-effectiveness ratio (ICER) for edoxaban compared with warfarin was £12,881 per QALY gained. At a threshold of £20,000 per QALY, the net monetary benefit associated with edoxaban was £1,406. Edoxaban was also cost effective compared with warfarin in higher risk (CHADS2≥ 3) and higher anticoagulant control (cTTR≥ 60%) subgroups (ICER £7,012 and £20,376 per QALY, respectively). Sensitivity analyses support these findings, and show that conclusions are robust to alternative assumptions about model inputs. Starting age, edoxaban cost, monitoring costs and mortality due to non-ICH major bleeds are the drivers of the results. PSA indicates that 82% of simulations are in the north-east quadrant of the costeffectiveness plane for this comparison, and that the probability that edoxaban is cost-effective versus warfarin is more than 50%. ConClusions: Compared with warfarin, edoxaban represents a cost-effective alternative for stroke prevention in UK patients with NVAF.
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Cost-Utility AnAlysis of ChoColAte ConsUmPtion for PreVention of CArdiometAboliC diseAse
O'Day K, Campbell DJ Xcenda, Palm Harbor, FL, USA objeCtives: Randomized controlled trials have shown favorable effects of polyphenols and flavonoids found in chocolate on various cardiometabolic risk factors, including inflammatory markers, blood pressure, lipids, and insulin sensitivity. Epidemiologic studies also suggest chocolate may reduce risks of cardiometabolic diseases. This study aims to assess the cost-utility of chocolate consumption from a US health system perspective. Methods: A cohort life-table analysis was developed to model life years (LYs) and quality-adjusted life years (QALYs) of chocolate consumption versus non-consumption over a lifetime horizon in US adults. Ageand sex-specific disease incidence and mortality rates were used to model outcomes of cardiometabolic diseases, including coronary heart disease, stroke, and diabetes. Relative risks of cardiometabolic disease associated with chocolate consumption were obtained from meta-analyses of prospective cohort and cross-sectional studies. Utility weights, baseline healthcare costs, and attributable disease costs were obtained from the literature. Costs of chocolate were estimated based on "high" consumption, consisting of three 150mg chocolate bars per week. Outcomes included undiscounted LYs and discounted costs and QALYs. Incremental analyses, stratified by sex, and probabilistic sensitivity analyses (PSAs) were conducted. Results: Chocolate consumption, compared to none, increased undiscounted LYs by 0.74 and 0.99 years and discounted QALYs by 0.54 and 0.45 years for males and females, respectively. Cardiometabolic disease costs were reduced by $7,763 and $6,318 and total healthcare costs were reduced by $5,660 and $2,717 for males and females, respectively. The incremental cost per QALY for chocolate consumption was $1,482 for males and $8,931 for females. In the PSA chocolate consumption had a 97.8% and 89.9% probability of being cost-effective for males and females, respectively, at a $50,000/QALY threshold. ConClusions: Chocolate consumption may be a costeffective means to reduce the risk of cardiometabolic disease. Given the limitations of observational study data, further research is warranted to confirm these findings. objeCtives: To conduct an economic evaluation comparing ranolazine plus standard-of-care (SoC) relative to SoC alone, in patients with chronic stable angina who did not respond adequately to first line therapy, in Greece. Methods: A decision tree model was locally adapted in the Greek setting to evaluate the cost-utility of comparators during a 6-month period. The analysis was conducted from a payer (sickness fund) perspective. The clinical inputs were extracted from the published literature. The cost inputs considered reflect drug acquisition, hospitalizations, vascular interventions and monitoring of patients. Resource utilization data were obtained from 3 local experts. All costs refer to the year 2014. Cost-effectiveness was assessed by means of the incremental cost per quality adjusted life year (QALY) saved with the ranolazine as add-on therapy, relative to SoC alone (ICER). Probabilistic sensitivity analysis (PSA) was performed. Results: Ranolazine as add-on therapy was more costly compared to SoC alone, as the 6-month total cost per patient was € 1,170 and € 984, respectively. Patients received ranolazine plus
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